Hormonal showdown: which treatment tames heavy periods in bleeding disorders?

NCT ID NCT05916469

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 300 teens and young adults (ages 10-24) with inherited bleeding disorders who choose either a levonorgestrel IUD or norethindrone acetate pills for heavy menstrual bleeding. Researchers will track bleeding patterns, satisfaction, and quality of life over six months to see which option works better. The goal is to provide clear guidance on managing heavy periods in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Levonorgestrel intrauterine system (LNG-IUD) and norethindrone acetate (NETA)

What this could lead to

If this study succeeds, it could help doctors choose the best hormonal treatment for heavy menstrual bleeding in young people with bleeding disorders, improving their quality of life.

What could go wrong

This is an observational study, not a randomized trial, so results may be less definitive. The study is also relatively small and focused on a specific age group, so findings may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAVY MENSTRUAL BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemorrhagic disease hereditary von Willebrand disease Menorrhagia vascular hemostatic disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Mercy

    NOT_YET_RECRUITING

    Kansas City, Missouri, 64108, United States

  • Colorado Anschutz Medical Campus

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • Emory

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Penn State Health

    NOT_YET_RECRUITING

    Hershey, Pennsylvania, 17003, United States

  • Seattle Children's Hospital

    NOT_YET_RECRUITING

    Seattle, Washington, 98105, United States

  • Stanford

    NOT_YET_RECRUITING

    Palo Alto, California, 94304, United States

  • University of Michigan Medicine

    NOT_YET_RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Washington

    NOT_YET_RECRUITING

    Seattle, Washington, 98101, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••